StocksMedium•30 September 2026•
1 min read
Santhera Pharmaceuticals H1 Revenue Doubles, Reaffirms 2026 Guidance
Key Facts
1Santhera Pharmaceuticals' first-half group revenue doubled to CHF 48.3 million.
2The company left its full-year 2026 revenue guidance of CHF 80 million to CHF 90 million unchanged.
3Stifel maintained a 'buy' rating and a CHF 25 price target on the stock.
Santhera Pharmaceuticals' first-half group revenue doubled to CHF 48.3 million. Proactive Investors reported that the company left its full-year 2026 revenue guidance of CHF 80 million to CHF 90 million unchanged. The sales growth was primarily driven by the company's neuromuscular drug portfolio.
Stifel maintained a 'buy' rating and a CHF 25 price target on the stock, noting that the reaffirmation of guidance provided stability for analyst valuations. This financial performance follows a period of monetary stability in Switzerland, where the interest rate decision remained at 0% on September 24, 2026.